Android app Apple app link

GSK gains approval in Japan for extended indication of RSV vaccine

By Yahoo! Finance   |   1 year ago
GSK gains approval in Japan for extended indication of RSV vaccine

Japan's Ministry of Health has approved GlaxoSmithKline's RSV vaccine, Arexvy, for individuals aged 50 to 59 at risk, expanding its use from those aged 60 and above.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.